An artificial intelligence (AI) Macular Disease treatment decision tool for patients with wet age-related macular degeneration, diabetic macular oedema, and retinal vein occlusion.

三种常见疾病影响眼球后部的中心，并导致毁灭性的视力丧失和失明：1)湿性年龄相关性黄斑变性（AMD）；ii)糖尿病性黄斑水肿（DMO）；iii)。视网膜静脉阻塞（RVO）最近在眼部成像和治疗方面的突破已经改变了这些疾病患者的治疗结果，最显著的是通过玻璃体内注射。然而，由于人口老龄化和糖尿病等与生活方式有关的疾病的增加，对这些注射的需求出现了惊人的增长。因此，没有足够的合格和训练有素的临床医生来提供这些重要的治疗。病人的延误导致失明病例增加，卫生系统正在努力满足需求。Macusoft将使用复杂的软件来自动化和支持推荐患者治疗的方式，使眼科医生能够花更多的时间对需要的患者进行视力保护治疗。这将确保更多的患者得到及时的治疗，并防止更多的永久性视力丧失。该软件将经过严格的测试，以便我们知道它运行良好，准确且安全。这款软件将让更多的病人得到诊治，帮助负担过重的眼科诊所应对日益增长的服务需求。我们的研究计划是开发软件，用对照研究来测试它，这样我们就知道它运行良好，准确，安全。一旦测试成功，它将在NHS和全世界范围内使用，帮助更多的患者接受他们需要的治疗。

Three common diseases affect the centre of the back of the eye and cause devastating loss of vision and blindness: i) wet Age- related Macular Degeneration (AMD); ii) Diabetic Macula Oedema (DMO), and; iii). Retinal Vein Occlusion (RVO).Recent breakthroughs in imaging of the eye and in treatments have transformed the outcome for patients with these diseases, most notably through intravitreal injections. However, there has been a staggering increase in the need for these injections, caused by our ageing population and the rise in lifestyle-related diseases such as diabetes. As a result, there aren't enough qualified and trained clinicians to provide these important treatments. Delays are occurring for patients leading to a rise in cases of sight loss, and health systems are struggling to keep up with demand.Macusoft will use sophisticated software to automate and support the way in which patients are recommended for treatment, enabling ophthalmologists to spend more of their time on administering sight-preserving treatments to patients who need them. This will ensure that more patients are treated in a timely manner, and that more permanent sight loss is prevented. The software will be rigorously tested so that we know it works well, is accurate and is safe.This software will allow more patients to be seen and treated, helping overburdened eye clinics to deal with the increased demand for their services.Our research plan is to develop the software, to test it with a controlled research study so that we know it works well, is accurate and is safe. Once tested it will then be made available for use across the NHS and worldwide, helping many more patients to receive the treatment they need.